GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

GSK PLC, (OTC:GLAXF),has been noted by broker Berenberg, which highlights a potential easing of challenges that have impacted ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

with an average P/E of 36.1. the group comprises Merck KGaA at 29, Zoetis at 35.5, CSL at 37.8, and AstraZeneca at 42. The same extreme relative undervaluation for GSK also applies to the ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...